Last reviewed · How we verify
LB-100 plus Doxorrubicin
At a glance
| Generic name | LB-100 plus Doxorrubicin |
|---|---|
| Sponsor | Grupo Espanol de Investigacion en Sarcomas |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LB-100 plus Doxorrubicin CI brief — competitive landscape report
- LB-100 plus Doxorrubicin updates RSS · CI watch RSS
- Grupo Espanol de Investigacion en Sarcomas portfolio CI